PFIZER INC
Tremor tracks 67 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- PFEPfizer0Calm
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Running, no new patientsPhase 1/274 patientsMain results: Oct 25, 2027 - PFEPfizer0Calm
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Running, no new patientsPhase 31,054 patientsMain results: Oct 3, 2022 - PFEPfizer0Calm
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Running, no new patientsPhase 3841 patientsMain results: Mar 1, 2025 - PFEPfizer0Calm
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Running, no new patientsPhase 3599 patientsMain results: Feb 18, 2026 - PFEPfizer0Calm
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Signing up patientsPhase 3680 patientsMain results: Mar 10, 2028 - PFEPfizer0Calm
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Running, no new patientsPhase 3609 patientsMain results: Feb 28, 2027 - PFEPfizer0Calm
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Signing up patientsPhase 3600 patientsMain results: Jun 1, 2029 - PFEPfizer0Calm
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Signing up patientsPhase 3900 patientsMain results: Sep 30, 2027 - PFEPfizer0Calm
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Signing up patientsPhase 1/2430 patientsMain results: Oct 7, 2029 - PFEPfizer0Calm
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Signing up patientsPhase 31,060 patientsMain results: Oct 18, 2030 - PFEPfizer0Calm
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Running, no new patientsPhase 31,068 patientsMain results: Jan 31, 2023 - PFEPfizer0Calm
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Not started yetPhase 33,800 patientsMain results: Apr 13, 2032 - PFEPfizer0Calm
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Signing up patientsPhase 2320 patientsMain results: Aug 27, 2029 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Running, no new patientsPhase 3240 patientsMain results: Jan 23, 2026 - PFEPfizer0Calm
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Running, no new patientsPhase 377 patientsMain results: Dec 31, 2026 - PFEPfizer0Calm
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Signing up patientsPhase 3400 patientsMain results: Jul 22, 2027 - PFEPfizer0Calm
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Running, no new patientsPhase 31,035 patientsMain results: Jan 2, 2029 - PFEPfizer0Calm
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Running, no new patientsPhase 31,068 patientsMain results: Dec 2, 2024 - PFEPfizer0Calm
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Signing up patientsPhase 2/3982 patientsMain results: Jan 23, 2028 - PFEPfizer0Calm
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Signing up patientsPhase 31,000 patientsMain results: Sep 12, 2028 - PFEPfizer0Calm
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Signing up patientsPhase 2/3840 patientsMain results: Jul 22, 2031 - PFEPfizer0Calm
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Signing up patientsPhase 240 patientsMain results: Mar 24, 2028 - PFEPfizer0Calm
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Signing up patientsPhase 1/2132 patientsMain results: Dec 28, 2027 - PFEPfizer0Calm
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Signing up patientsPhase 1/2224 patientsMain results: Nov 2, 2027 - PFEPfizer0Calm
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Signing up patientsPhase 2120 patientsMain results: Jul 29, 2028 - PFEPfizer0Calm
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Signing up patientsPhase 31,410 patientsMain results: Feb 27, 2029 - PFEPfizer0Calm
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Signing up patientsPhase 1/2138 patientsMain results: Oct 18, 2027 - PFEPfizer0Calm
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Signing up patientsPhase 3800 patientsMain results: Feb 23, 2030 - PFEPfizer0Calm
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Signing up patientsPhase 1/2162 patientsMain results: Mar 8, 2029 - PFEPfizer0Calm
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Signing up patientsPhase 2/3550 patientsMain results: Jun 14, 2030 - PFEPfizer0Calm
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
FinishedPhase 2128 patientsMain results: Aug 26, 2024 - PFEPfizer0Calm
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Running, no new patientsPhase 1/271 patientsMain results: Sep 5, 2025 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Running, no new patientsPhase 3654 patientsMain results: Sep 5, 2025 - PFEPfizer0Calm
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Signing up patientsPhase 3714 patientsMain results: Sep 5, 2028 - PFEPfizer0Calm
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Signing up patientsPhase 2100 patientsMain results: May 21, 2033 - PFEPfizer0Calm
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Running, no new patientsPhase 1/2235 patientsMain results: Feb 26, 2027 - PFEPfizer0Calm
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Running, no new patientsPhase 266 patientsMain results: Jul 17, 2023 - PFEPfizer0Calm
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Running, no new patientsPhase 235 patientsMain results: Dec 31, 2029 - PFEPfizer0Calm
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Running, no new patientsPhase 3257 patientsMain results: Oct 30, 2026 - PFEPfizer0Calm
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Running, no new patientsPhase 1/237 patientsMain results: Mar 24, 2027 - PFEPfizer0Calm
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Signing up patientsPhase 3893 patientsMain results: Feb 26, 2026 - PFEPfizer0Calm
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Signing up patientsPhase 3492 patientsMain results: Aug 30, 2026 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Running, no new patientsPhase 2217 patientsMain results: Nov 1, 2023 - PFEPfizer0Calm
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Running, no new patientsPhase 2333 patientsMain results: Jan 12, 2026 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
FinishedPhase 282 patientsMain results: May 9, 2024 - PFEPfizer0Calm
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
Running, no new patientsPhase 2108 patientsMain results: Jun 19, 2026 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Running, no new patientsPhase 3762 patientsMain results: May 18, 2026 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Running, no new patientsPhase 3466 patientsMain results: Jun 29, 2023 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Running, no new patientsPhase 2350 patientsMain results: Mar 20, 2026 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Running, no new patientsPhase 254 patientsMain results: Jul 28, 2029 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Running, no new patientsPhase 2120 patientsMain results: Mar 27, 2026 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Running, no new patientsPhase 3412 patientsMain results: Jan 29, 2027 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Signing up patientsPhase 3400 patientsMain results: Dec 31, 2027 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Signing up patientsPhase 2372 patientsMain results: Dec 11, 2026 - PFEPfizer0Calm
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
FinishedPhase 2121 patientsMain results: Jul 10, 2025 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
FinishedPhase 2161 patientsMain results: Feb 3, 2026 - PFEPfizer0Calm
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
FinishedPhase 2187 patientsMain results: Mar 13, 2024 - PFEPfizer0Calm
PF-07104091 as a Single Agent and in Combination Therapy
Running, no new patientsPhase 2157 patientsMain results: Dec 31, 2026 - PFEPfizer0Calm
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Running, no new patientsPhase 3854 patientsMain results: Aug 4, 2027 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
FinishedPhase 270 patientsMain results: Jul 15, 2024 - PFEPfizer0Calm
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
Running, no new patientsPhase 3624 patientsMain results: Jan 31, 2025 - PFESeagen, a wholly owned subsidiary of Pfizer0Calm
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Running, no new patientsPhase 240 patientsMain results: Jul 31, 2024 - PFEPfizer0Calm
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Running, no new patientsPhase 359 patientsMain results: Dec 30, 2026 - PFESeagen Inc.0Calm
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
FinishedPhase 1/2185 patientsMain results: Sep 30, 2024 - PFEPfizer0Calm
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Running, no new patientsPhase 3296 patientsMain results: Mar 20, 2020 - PFESeagen Inc.0Calm
A Study of SEA-CD40 Given With Other Drugs in Cancers
FinishedPhase 277 patientsMain results: Jan 3, 2024 - PFESeagen Inc.0Calm
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
FinishedPhase 2/317 patientsMain results: Apr 17, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
2 sales (2 not pre-planned) · 3 purchases
- BOURLA ALBERTChairman & CEO · Aug 12, 2026Bought 38,000 sharesabout $1.0 million ·
- DAMICO JENNIFER B.SVP & Controller · Aug 5, 2026Sold 3,278 sharesabout $83 thousand · not pre-planned
- BLAYLOCK RONALD EBoard member · Aug 5, 2026Bought 39,231 sharesabout $999 thousand ·
- Buckley Mortimer JBoard member · Aug 5, 2026Bought 37,632 sharesabout $960 thousand ·
- DAMICO JENNIFER B.SVP & Controller · Jun 9, 2026Sold 2,000 sharesabout $51 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.